Where Are We With Cardiac Amyloidosis?

Join us for an exclusive educational program designed to elevate your expertise in managing transthyretin cardiac amyloidosis (ATTR-CA) within the realm of heart failure (HF). Our goal is to enrich your understanding of this challenging condition and its implications for patient care. 

Explore the latest advancements in FNA interference therapies, TTR stabilizers, and silencers/knockdown agents, and learn how these innovations can revolutionize your approach to treating ATTR-CA alongside heart failure and arrhythmia management. 

Gain insights from leading experts as they delve into current diagnostic practices, unveil groundbreaking data on new therapies, and engage in dynamic panel discussions on the future landscape of cardiac amyloidosis management. 

Don’t miss this opportunity to expand your knowledge, network with peers, and discover new strategies to optimize patient outcomes. Secure your place today and be at the forefront of transforming care for patients with ATTR-CA. 

An accredited satellite program, provided by HFSA and supported through an independent educational grant from Alnylam Pharmaceuticals